GlassScriptPhysician profile
Manali R Shah
NPI 1164664363
$4,583.01
in general payments reported to CMS, 2019-2025
48 companies · $1,486 in 2025
The $1,486 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $410 · 2023: $1,266 · 2024: $1,422 · 2025: $1,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $508.60 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $441.60 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $427.99 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $277.31 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Janssen Biotech, INC. | $266.36 | 2022-2025 | Erleada, Rybrevant, Akeega |
| Daiichi Sankyo INC. | $153.10 | 2022-2025 | Enhertu, Datroway |
| Pfizer INC. | $152.48 | 2022-2025 | |
| Gilead Sciences, INC. | $152.18 | 2023-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $142.45 | 2023-2025 | Ojjaara, Shingrix |
| Sobi, INC | $140.06 | 2023-2024 | |
| Astellas Pharma US INC | $137.45 | 2023-2025 | Padcev, Vyloy |
| Jazz Pharmaceuticals INC. | $115.43 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.10 | 2022-2025 | |
| Eisai INC. | $91.03 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.14 | 2023-2024 | Alunbrig |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $87.37 | 2022-2023 | Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $87.30 | 2025 | Opdivo |
| Emd Serono, INC. | $83.11 | 2025 | |
| Lilly USA, LLC | $76.36 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $70.79 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Beone Medicines USA, INC. | $64.68 | 2025 | Brukinsa |
| Genentech USA, INC. | $62.60 | 2023-2024 | Venclexta, Phesgo, Polivy |
| Seagen INC. | $59.91 | 2023 | Adcetris, Tivdak |
| Abbvie INC. | $58.53 | 2024-2025 | |
| Genzyme Corporation | $57.63 | 2025 | |
| Pharmaessentia USA Corporation | $55.72 | 2025 | Besremi |
| Servier Pharmaceuticals LLC | $49.41 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $48.85 | 2022-2023 | Xpovio |
| Exelixis INC. | $42.82 | 2023-2024 | Cabometyx |
| Puma Biotechnology, INC. | $42.36 | 2022-2023 | Nerlynx |
| Genmab U.S., INC. | $41.97 | 2024 | Epkinly |
| Csl Behring | $34.75 | 2023 | Afstyla, Idelvion |
| Legend Biotech USA INC. | $34.36 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $34.22 | 2025 | Zoladex |
| Stemline Therapeutics INC. | $33.47 | 2023-2024 | Orserdu |
| Deciphera Pharmaceuticals INC. | $32.89 | 2023-2024 | Qinlock |
| Kyowa Kirin, INC. | $26.01 | 2025 | |
| Geron Corporation | $23.68 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $20.75 | 2024 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $20.06 | 2023 | Monoferric |
| Recordati_rare_diseases_inc. | $18.25 | 2025 | Enjaymo |
| Regeneron Healthcare Solutions, INC. | $17.46 | 2024 | Libtayo |
| Array Biopharma INC | $17.34 | 2025 | Ibrance |
| Myovant Sciences INC. | $16.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.64 | 2023 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $13.39 | 2023 | Yonsa, Odomzo |
| Ipsen Biopharmaceuticals, INC | $12.75 | 2022 | |
| Adaptive Biotechnologies Corporation | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manali Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.